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Background:  It is unclear whether rosuvastatin was different from atorvastatin on preventing contrast induced nephropathy (CIN) in 
patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI).
methods:  We enrolled 1078 consecutive patients with CKD undergoing elective PCI. Patients in Group 1 (n=273) received rosuvastatin 
(10mg), and those in group 2 (n= 805) received atorvastatin (20mg).
results:  CIN was observed in 58 (5.4%) patients. The incidence of CIN was similar in patients pretreated with either rosuvastatin or 
atorvastatin (5.9% vs. 5.2%, p=0.684). The same results were also observed when using other definitions of CIN. Clinical and procedural 
characteristics did not show significant differences between the two groups (p>0.05). Additionally, there were no significant inter-group 
differences with respect to in-hospital mortality rates (0.4% vs. 1.5%, p=0.141). Multivariate logistic regression analysis revealed that 
rosuvastatin and atorvastatin demonstrated similar efficacies for preventing CIN, after adjusting for potential confounding risk factors 
(OR=1.17,95% CI,0.62-2.20,p=0.623). A Kaplan-Meier survival analysis showed that patients taking either rosuvastatin or atorvastatin had 
similar incidences of all-cause mortality (9.4% vs.7.1%,respectively;p=0.290) during follow-up.
Conclusion:  Rosuvastatin and atorvastatin have similar efficacies for preventing CIN in patients with CKD undergoing PCI. 
